Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results

PharmaVoiceFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech

Endpoints NewsM&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts

LabiotechCAR-T therapy for stiff person syndrome nears approval

Endpoints NewsAndrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirement

Endpoints News#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes live

FierceBiotechAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects

LabiotechFreeze variability, not progress: strengthen your cell therapy supply chain from the start

Endpoints NewsSupreme Court preserves mail access for abortion pill

FierceBiotechAardvark to dig into phase 3 data early after FDA imposes hold

Siemens HealthineersSiemens Healthineers Wins Key US Clearances As Valuation Gap Widens - simplywall.st

BioNTechBioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends - AD HOC NEWS

Every GreenBiotech Just Hit Fast Forward. Is Europe’s Seed Sector Ready? - seedworld.com